Copyright (c) 2009 Yahoo! Inc. All rights reserved.http://finance.yahoo.com/q/h?s=hephLatest Financial News for Hollis-Eden Pharmaceuticals, Inen-usTue, 8 Dec 2009 18:46:04 Etc/GMThttp://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gifhttp://finance.yahoo.com14417http://us.rd.yahoo.com/finance/external/cnbc/rss/SIG=11h3var1f/*http%3A//www.cnbc.com/id/34328996/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahooyahoo_finance/2309167608Tue, 8 Dec 2009 18:46:04 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091116/heph8-k.htmlyahoo_finance/860482751Mon, 16 Nov 2009 20:00:40 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091116/la11514.html?.v=1Hollis-Eden Pharmaceuticals, Inc. , today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® for hormone-resistant prostate cancer .yahoo_finance/2575311746Mon, 16 Nov 2009 14:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/q/is?s=hephyahoo_finance/748360017Fri, 13 Nov 2009 14:05:29 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091112/la10597.html?.v=1Hollis-Eden Pharmaceuticals, Inc. , will present results of its ongoing human clinical Phase I/II open-label dose-ranging trial with Apoptone® for hormone-resistant prostate cancer on November 16 at the American Association for Cancer Research - Molecular Targets and Cancer Therapeutics Conference in Boston.yahoo_finance/2549877946Thu, 12 Nov 2009 21:37:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091106/heph10-q.htmlyahoo_finance/111807699Fri, 6 Nov 2009 22:23:05 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091022/heph8-k.htmlyahoo_finance/146286331Thu, 22 Oct 2009 10:05:18 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091020/la95212.html?.v=1Hollis-Eden Pharmaceuticals has retained Burrill LLC to provide exclusive strategic advisory services, with an initial focus on partnering Hollis-Eden's lead program Apoptone, currently in Phase I/II development for hormone-refractory prostate cancer.yahoo_finance/1111845277Tue, 20 Oct 2009 13:11:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090916/heph8-k.htmlyahoo_finance/311515818Wed, 16 Sep 2009 17:33:58 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090814/heph10-q.htmlyahoo_finance/437879452Fri, 14 Aug 2009 10:06:08 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090615/heph8-k.htmlyahoo_finance/103743814Mon, 15 Jun 2009 16:30:56 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090611/heph8-k.htmlyahoo_finance/2132970634Thu, 11 Jun 2009 20:54:39 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090605/heph8-k.htmlyahoo_finance/4034961087Fri, 5 Jun 2009 20:06:17 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090514/heph10-q.htmlyahoo_finance/2592860513Thu, 14 May 2009 10:03:05 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090423/heph8-k.htmlyahoo_finance/798422037Thu, 23 Apr 2009 21:00:52 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090331/heph8-k.htmlyahoo_finance/1943352687Tue, 31 Mar 2009 21:30:42 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090331/heph10-k.htmlyahoo_finance/1656009174Tue, 31 Mar 2009 21:28:45 Etc/GMThttp://us.rd.yahoo.com/finance/external/tsmfe/rss/SIG=12s2shgmu/*http://www.thestreet.com/_yahoo/story/10476417/1/hollis-eden-namesake-fired-for-cause.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NAyahoo_finance/18352882Tue, 24 Mar 2009 05:30:30 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090323/heph8-k.htmlyahoo_finance/3204423948Mon, 23 Mar 2009 20:36:07 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/090204/heph8-k.htmlyahoo_finance/4287912236Wed, 4 Feb 2009 11:02:59 Etc/GMT